Compass Pathways (NASDAQ:CMPS) Now Covered by B. Riley Financial

B. Riley Financial assumed coverage on shares of Compass Pathways (NASDAQ:CMPS) in a report issued on Friday, Marketbeat reports. The brokerage issued a buy rating and a $17.00 price objective on the stock.

A number of other research firms have also recently issued reports on CMPS. Compass Point set a $15.00 price target on Compass Pathways in a report on Thursday, February 12th. BTIG Research reissued a “buy” rating and set a $14.00 price objective on shares of Compass Pathways in a report on Monday, April 20th. Canaccord Genuity Group dropped their price objective on Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, March 26th. HC Wainwright boosted their price objective on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Compass Pathways presently has an average rating of “Moderate Buy” and a consensus target price of $20.70.

Compass Pathways Stock Performance

Compass Pathways stock opened at $9.58 on Friday. The stock has a 50-day simple moving average of $6.68 and a 200 day simple moving average of $6.46. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $10.21. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -3.10 and a beta of 2.01.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). On average, research analysts anticipate that Compass Pathways will post -1.68 earnings per share for the current fiscal year.

Institutional Trading of Compass Pathways

Institutional investors and hedge funds have recently modified their holdings of the stock. Corient Private Wealth LLC boosted its position in Compass Pathways by 3.2% during the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after acquiring an additional 1,200 shares during the last quarter. CWM LLC boosted its position in Compass Pathways by 19.2% during the 3rd quarter. CWM LLC now owns 15,650 shares of the company’s stock worth $90,000 after acquiring an additional 2,525 shares during the last quarter. Conservest Capital Advisors Inc. boosted its holdings in shares of Compass Pathways by 24.6% in the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after buying an additional 5,000 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways in the 4th quarter valued at approximately $38,000. Finally, Raymond James Financial Inc. boosted its holdings in shares of Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after buying an additional 6,228 shares during the last quarter. 46.19% of the stock is owned by institutional investors.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.